CapDecisif et al. in €3.6m round for InnaVirVax
A consortium of existing backers, including CapDecisif Management and Fa Dièse, have injected a further €3.6m into HIV-focused French biopharma InnaVirVax.
The company's investors that took part in this latest round include CapDecisif (investing via its FCPR CapDecisif 2 vehicle), seed fund G1J Ile-de-France, family fund Pradeyrol Development, Fa Dièse and FRCI (Fonds Régional de Co-Investissement d'Ile-de-France).
InnaVirVax is now aiming to accelerate the development of its VAC-3S product, which is currently in phase-two clinical trials and is designed to restore the immune system of people living with HIV.
Company
Founded in 2008, InnaVirVax develops therapeutic solutions for infectious diseases and major chronic diseases. It is currently focusing on HIV treatment with its VAC-3S product.
People
Catherine Boule led the deal for CapDecisif.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








